Becton Dickinson and Lab21 announce collaboration agreement BD Diagnostics, a segment of Becton Dickinson and Lab21 announced that they will collaborate to develop oncology assays for the BD MAX(TM) fully automated, bench-top molecular system. Under the terms of the collaboration, Lab21 will develop polymerase chain reaction-based assays on the BD MAX platform for a series of oncology markers. BD will be responsible for manufacturing and commercializing the tests worldwide. The first two assays will be designed to detect mutations in the KRAS and BRAF genes. These initial assays were selected because of their current importance in optimizing the management of cancer patients. The agreement also includes the development of novel nucleic acid extraction procedures from formalin-fixed paraffin-embedded tissue.
News For BDX From The Last 14 Days
Check below for free stories on BDX the last two weeks.
JDRF extends collaboratoin with Becton Dickinson JDRF and Becton Dickinson are accelerating the development of new products that combine BD's proprietary insulin infusion and glucose sensing technologies through a new collaboration announced. This new, three-year commitment is an extension of existing JDRF-BD collaborations focused on type 1 diabetes.
Becton Dickinson price target raised to $115 from $95 at Argus Argus increased its price target on Becton Dickinson as the firm expects the company to benefit from its new generic drug manufacturing business. The firm notes that this new business has high margins, and it keeps a Buy rating on the shares.